Avidity Biosciences Q2 EPS $(0.65) Beats $(0.79) Estimate, Collaboration Revenue $2.04M Miss $2.64M Estimate

Author: Benzinga Newsdesk | August 09, 2024 04:12pm
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.79) by 17.72 percent. This is a 1.52 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $2.04 million which missed the analyst consensus estimate of $2.64 million by 22.54 percent. This is a 11.70 percent decrease over sales of $2.32 million the same period last year.

Posted In: RNA